Vogenx Inc’s Quiet Period Set To End on September 21st (NASDAQ:VOGX)

Vogenx’s (NASDAQ:VOGX) quiet period will expire on Monday, September 21st. Vogenx had issued 6,250,000 shares in its initial public offering on August 12th. The total size of the offering was $81,250,000 based on an initial share price of $13.00. During the company’s quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on VOGX. Wall Street Zen raised Vogenx to a “hold” rating in a research note on Saturday, August 22nd. JonesTrading started coverage on shares of Vogenx in a research report on Tuesday, September 1st. They set a “buy” rating and a $55.00 price objective on the stock. Finally, WBB Securities assumed coverage on shares of Vogenx in a research note on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating and one has given a Buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Strong Buy” and an average price target of $48.50.

Vogenx Stock Up 2.2%

Shares of NASDAQ:VOGX opened at $34.13 on Friday. Vogenx has a 1 year low of $12.95 and a 1 year high of $36.00.

Vogenx (NASDAQ:VOGX) last announced its quarterly earnings results on Thursday, September 17th. The company reported ($0.07) EPS for the quarter.

About Vogenx

Vogenx, Inc was a biotechnology company focused on the discovery and development of novel therapies for inflammatory and metabolic diseases. Its research activities centered on small-molecule drug candidates intended to address conditions associated with chronic inflammation and immune-system dysfunction.

The company’s lead investigational compound was VGX-1027, an orally administered candidate studied for its potential anti-inflammatory and immunomodulatory effects. Publicly available information describes research applications involving diseases such as diabetes and other inflammatory disorders, although the company’s development programs were not established as widely marketed commercial products.

Vogenx was based in the United States and operated as a development-stage biopharmaceutical company.